Navigation Links
Replidyne Discontinues Phase III Trial
Date:4/23/2008

st-line antibiotic for treatment of respiratory and skin infections in adult and pediatric patients. Replidyne's investigational antibacterial agent REP3123 targets Gram-positive C. difficile bacteria and C. difficile- associated disease (CDAD). Replidyne is pursuing the development of other novel anti-infective programs based on its DNA replication inhibition technology and its in-house discovery research.

Safe Harbor

This press release contains plans, intentions, objectives, estimates and expectations that constitute forward-looking statements about Replidyne, Inc. that involve significant risks and uncertainties. Actual results could differ materially from those discussed due to a number of factors including, the success and timing of pre-clinical studies and clinical trials; the Company's ability to obtain a new partner for faropenem on acceptable terms; the Company's ability to obtain and maintain regulatory approval of product candidates and the labeling under any approval that may be obtained; plans to develop and commercialize product candidates; the loss of key scientific or management personnel; the size and growth of the potential markets for the Company's product candidates and the Company's ability to serve those markets; regulatory developments in the U.S. and foreign countries; the rate and degree of market acceptance of any future products; the accuracy of Company estimates regarding expenses, future revenues and capital requirements; the Company's ability to obtain and maintain intellectual property protection for our product candidates; the successful development of the Company's sales and marketing capabilities; the success of competing drugs that are or become available; and the performance of third party manufacturers. These and additional risks and uncertainties are described more fully in the Company's most recent Form 10-K filed with the SEC under the Securities Exchange Act of 1934. Copies of filings made with the SEC are avail
'/>"/>

SOURCE Replidyne, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Replidyne Provides Strategic Update
2. Replidyne to Participate on Anti-infective Panel at RBC Capital Markets Healthcare Conference
3. Replidynes Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile
4. Replidynes Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile
5. Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
6. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
7. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
8. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
9. Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
10. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
11. Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013 The Physician-Patient Alliance for ... fatigue. The need to urgently address this issue ... Sentinel Event Alert #50 , "Medical device alarm safety in ... between January 2008 and June 2012, there were 98 alarm ... in death (82%) , 13 resulted in permanent loss ...
(Date:6/19/2013)... , June 19, 2013  Caradigm today ... a solution designed to help healthcare organizations ... data while supporting their compliance with data ... represents a milestone in the delivery of ... capabilities for health systems. ...
(Date:6/19/2013)... , June 19, 2013  Finesse Solutions, Inc, ... life sciences process applications, announced the launch of ... upstream cell culture and fermentation.  The 3L glass ... family of Finesse bioreactors and are designed to ... They are fully compatible with all Finesse G3Lab ...
Breaking Medicine Technology:Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 2Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 3Caradigm Provisioning Helps Healthcare Organizations Improve Clinical Efficiency, Manage Risk 2Caradigm Provisioning Helps Healthcare Organizations Improve Clinical Efficiency, Manage Risk 3Finesse Solutions Launches Next Generation SmartGlass 3L Bioreactors for Cell Culture and Fermentation 2
... how microbes can block nitric,oxide production - a chemical ... fighting bacteria, MEMPHIS, Tenn., Nov. 3 St. ... which,intracellular pathogens can shut down one of the body,s ... that the microbes,block nitric oxide production by subverting the ...
... presented at the 2008 iSBTc Annual Meeting -, ... a.m. ET to discuss,results -, BRANFORD, Conn., Nov. ... preliminary data from an ongoing Phase II,trial of CR011-vcMMAE, ... patients with unresectable Stage III or Stage IV melanoma.,Dr. ...
Cached Medicine Technology:Parasites That Live Inside Cells Use Loophole to Thwart Immune System 2Parasites That Live Inside Cells Use Loophole to Thwart Immune System 3CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 2CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 3CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 4CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 5CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 6CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 7
(Date:6/19/2013)... 19, 2013 Ultimate Medical Academy (UMA) ... 11.5-hour broadcast on WFLA News Channel 8. Since its ... than $84 million for All Children's Hospital in St. ... "30 Years of Miracles," marked the second year UMA ... employees worked the phones during the Telethon, which raised ...
(Date:6/19/2013)... 19, 2013 The former internist for ... Loomis, MD, now serves as director of prevention and ... was his own personal encounter with a metabolic syndrome ... Forks Over Knives , that he credits with sparking ... and his medical practice. , “The average medical student ...
(Date:6/19/2013)... MA (PRWEB) June 19, 2013 ... , a premier kids entertainment media organization, and ... serious games company, will be introducing the Games ... StudenTopia. The 3D game is geared toward students ... eating and active lifestyles by rewarding positive choices. ...
(Date:6/19/2013)... Imprivata ®, a leading global ... Imprivata OneSign ® leads the single sign-on (SSO) ... Software & Services report . CIOs and other healthcare ... superior performance of its products and the quality of ... Imprivata is integral to their long-term healthcare IT strategy. ...
(Date:6/19/2013)... Recently, SoCal CEO Magazine staff was on ... third in a series of six workshops where people with and ... place the mosaic tiles in their permanent location under the direction ... Greg Maxwell. , This mural project began in March of ... over three years ago with the goal of promoting ...
Breaking Medicine News(10 mins):Health News:Ultimate Medical Academy Rallies in Support of All Children's Hospital 2Health News:Ultimate Medical Academy Rallies in Support of All Children's Hospital 3Health News:Plant-based Nutrition is Key to Health Transformation of St. Luke’s Hospital Director of Prevention and Wellness 2Health News:Plant-based Nutrition is Key to Health Transformation of St. Luke’s Hospital Director of Prevention and Wellness 3Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 2Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 3Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 4Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 5Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 3Health News:Arc Creates Huge Mosaic Mural to Highlight the Need for Greater Respect of People with Disabilities 2
... for ORBIS Children,s Eye Care Project ... ... Pendyala, ages 8 and 6,will launch a kid-inspired and kid-driven campaign on ... goal is to raise $260,000 for a specialized pediatric eye care,unit and ...
... Congress to the economic hardship definition in the ... will deter physicians from pursuing careers in primary ... C. Dale, MD, FACP, president of the American ... committee leaders involved in the legislation. ACP ...
... Oct. 9 MGT Capital Investments,Inc. (Amex: ... on the Healthcare Information,Technology ("HCIT") sector, announced ... Medicexchange PLC, a global web portal that,delivers ... treatment and,surgery planning solutions across breast imaging, ...
... associated with 20 percent of all lung malignancies, scientists say ... that appear to work together are associated with 20 percent ... fetal lung development, researchers report. , Understanding how these genes ... forming, according to the report in this week,s issue of ...
... SAN DIEGO, Oct. 9 Many Americans are obsessed ... obsessed about being,mentally fit. More Americans are becoming aware ... society where knowledge, intelligence, and quick,wits are rewarded. Being ... to effectively train your brain have been lacking,until recently. ...
... Partners announced today that,it has initiated coverage on ... team was pivotal in getting two drugs,approved and ... biotech company and we believe they will do ... Research at Vista Partners. Vista Partners,provides independent, equity ...
Cached Medicine News:Health News:Elementary School Students to Launch 'Kids for Sight' Campaign, to Inspire Other Kids to Pay it Forward 2Health News:Elementary School Students to Launch 'Kids for Sight' Campaign, to Inspire Other Kids to Pay it Forward 3Health News:Revisions to 'College Cost Reduction and Access Act' will create barriers to primary care 2Health News:MGT Capital Investments Announces New Commercial Partnerships for Subsidiary Company Medicexchange PLC 2Health News:MGT Capital Investments Announces New Commercial Partnerships for Subsidiary Company Medicexchange PLC 3Health News:3 New Lung Cancer Genes Identified 2Health News:Online Game from BrainGrade Can Raise Brain I.Q. 2Health News:Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp. 2
... of Sleepscan VISION ensures flexibility in system ... Sleepscan VISION utilizes the powerful Netlink amplifier ... a standard Ethernet connection. Only computer industry ... the Sleepscan VISION to take advantage of ...
... 25 years, Bio-logic has demonstrated continuous innovations ... introduced the first Digital EEG system brings ... you! Ceegraph VISION is the first Windows ... to integrate all your EEG needs: epilepsy ...
... From the Pioneer in Digital ... first Digital EEG system presents the ... - the Ceegraph VISION. This innovative ... networking, remote communications and information management ...
... When you purchase an XLTEK Mobee, you're getting ... one. Both the Mobee32 and the Mobee O2 ... PSG recording, traditional in-lab EEG monitoring, or in-lab ... that allow for full 10/20 electrode placement. The ...
Medicine Products: